Inoviq Ltd · ASX:IIQ
Inoviq — Shareholder Meeting (November 2021)
20 slides from Inoviq's shareholder meeting presentation, Nov 29, 2021
Slide 1: Detecting cancer earlier to save lives
Detecting cancer earlier to save lives Annual General Meeting 29 November 2021 CEO Presentation BARD1 Life Sciences Ltd (ASX:BD1) BARD1 AGM Presentation 29 November 2021 Page 1 www.bard1.com | info@bard1.com
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by BARD1 Life Sciences Limited (“BARD1” or the “Company”) based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company’s activities current as at the date of th
Slide 3: Company overview
Company overview BARD1 Life Sciences (ASX: BD1) Financial information (ASX:BD1) • Lifesciences company initially focused on earlier cancer detection Ordinary shares 91,994,920 • Innovative technologies with strong IP protecting methods & use Share price (26/11/21) A$1.040 • Multi-product pipeline fo
Slide 4: Key achievements
Key achievements Commercial Research & Corporate Financial Development • hTERT revenues steady at $550k • Progressed SubB2M • Acquisition & integration of • Cash balance of $20.4m at pa, new lab users gained in US, immunoassay program with initial Sienna with focus on realising 30 September 2021 and
Slide 5: Unmet need for earlier cancer detection
Unmet need for earlier cancer detection Problem 5-year survival rates by stage at diagnosis1 Detection of early-stage cancers is often associated with high 120% false-positives &/or lack of sensitivity 96% 99% 98%100% Cancers often detected at late-stage after symptoms have 100% 90% 93% appeared
Slide 6: Global cancer diagnostics market
Global cancer diagnostics market Global cancer burden: 50.6m survivors, 19.3m new cases Lung Cancer Bladder Cancer and 10.0m deaths p.a.1 US$3.6b US$320m Global cancer diagnostics market valued at US$250b2 BARD1 is targeting markets worth over US$11b for some of the world’s most common and dea
Slide 7: Breast cancer | US screening market potential
7 Breast cancer | US screening market potential World’s most common cancer: 2.3m new cases & 685k deaths pa1 US: 3.7m survivors, 234k new cases & 43k deaths pa1,2 Life-time risk of 12.9% , increases to 55-70% with BRCA1 & 45-69% with BRCA2 mutations 2 Screening using mammography recommended
Slide 8: Ovarian cancer | US screening market potential
8 Ovarian cancer | US screening market potential World’s deadliest gynaecological cancer: 314k new cases & 207k deaths pa1 US: 235k survivors, 24k new cases & 14k deaths pa1,2 Life-time risk of 1.2%, increases to 35-70% with BRCA1 mutation 2,4 Average 5-year survival 49% due to late-stage de
Slide 9: Product and pipeline portfolio
Product and pipeline portfolio Before diagnosis After diagnosis • Commercial products for bladder cancer1 & exosome research Prognosis / • Multi-product pipeline focused on detection & monitoring of cancer Risk Screening Diagnosis Prediction Monitoring • Lead pipeline products for monitoring breast
Slide 10: SubB2M™ | technology and test method
SubB2M™ | technology and test method Game-changing technology for monitoring and detection of cancer SubB2M protein detects a unique cancer marker Neu5Gc found in human cancer tissues, cells & biofluids1 SubB2M immunoassay Exclusive worldwide licence to SubB2M technology for diagnostic applicati
Slide 11: Commercialisation | goals and strategy
Commercialisation | goals and strategy GOAL is to develop and commercialise accurate and reliable blood tests for earlier detection and monitoring • Prioritise development of SubB2M immunoassay for monitoring breast and ovarian cancers on Develop platform compatible with high-throughput laboratory w
Slide 12: SubB2M | breast cancer test
SubB2M | breast cancer test Monitoring and detection of breast cancer Data • POC study conducted by Griffith University to evaluate SubB2M SPR- Stage Breast Cancer1 based assay for detection of Neu5Gc in 118 samples of BC cases and n=118 (96 cancers : 22 controls) controls Sensitivity Specificity AU
Slide 13: SubB2M | ovarian cancer test
SubB2M | ovarian cancer test Monitoring and detection of ovarian cancer Data • POC study conducted by Griffith University to evaluate SubB2M SPR- Stage Ovarian Cancer n=69 (47 cancers : 22 controls) based assay for detection of Neu5Gc in 69 samples of OC cases and controls Sensitivity Specificity AU
Slide 14: EXO-NET | products & pipeline
EXO-NET | products & pipeline Enabling technology for exosome research, diagnostic and therapeutic applications RUO EXO-NET EXO-NET produc pipeline • RUO EXO-NET is a pan-exosome capture tool for research use • EXO-NET is a proprietary multi-layered matrix of capture antibodies • Suitable for enrich
Slide 15: EXO-NET | comparison data
EXO-NET | comparison data Scalable exosome isolation for high throughput screening Speed, purity and yield advantages Compatible with downstream exosomal RNA & protein analyses Exosomal mRNA Exosomal proteins GAPDH OAZ1 “EXO-NET enables simple and rapid exosome capture for clinical application
Slide 16: BARD1 | technology and autoantibody tests
BARD1 | technology and autoantibody tests • Splice variants of BARD1 are associated with cancer formation, progression and poor prognosis • BARD1 autoantibody (AAb) tests measure n Product Study AUC Sensitivity Specificity (cancer:normal) autoantibodies to BARD1 variants and use a weighted algorithm
Slide 17: hTERT | ICC test for detection of hTERT
hTERT | ICC test for detection of hTERT Anti-hTERT antibody Anti-hTERT Antibody • hTERT test is an immunocytochemistry (ICC) assay that detects hTERT • Adjunct to urine cytology to assist bladder cancer diagnosis • Registered in US (FDA Class I), Europe (CE-IVD mark), South Korea (MFDS Class II) & A
Slide 18: Catalysts
Catalysts Expected value-adding milestones over the next 12 months Key catalysts 4Q CY2020 • Further feasibility results for SubB2M immunoassay tests • Appoint CRO to advance assay development • Commence clinical studies for SubB2M breast and ovarian cancer tests • Contract manufacturing agreements
Slide 19: Summary
Summary Lifesciences • Focused on unmet needs for earlier detection of cancer to save lives company Game changing • Proprietary technologies with clear advantages for multiple cancer technology applications Strong pipeline • Multi-product pipeline for detection of common and deadly cancers Compellin
Slide 20: Contacts
Contacts BARD1 Life Sciences Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@bard1.com W www.bard1.com Dr Leearne Hinch | CEO E leearne@bard1.com M +61 400414416 BARD1 AGM Presentation 29 November 2021 Page 20